Citation tools
"Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen." Anticancer Research
38.11
(2018):
6399-6404.
Web. 18 April. 2024.